Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss

Leave a Comment / By Market Social / February 25, 2026

The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly’s Zepbound.

Post navigation

Your survival guide to watching Trump’s State of the Union

Bitcoin mining is no longer profitable after crypto’s latest downward turn, analyst says

Your email address will not be published. Required fields are marked *

Comment *

Name*

Email*

Website

Save my name, email, and website in this browser for the next time I comment.

Markets

Trading

About Us

Name * Only alphabets are allowed.

Password

Again Password

Referral (Optional)

Support Language

Whatsapp Number *

OTP